Chemical Structure (Buprenorphine 01)
Buprenorphine Patch
Product Images NDC 42858-493
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 42858-493). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rhodes Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Buprenorphine 02)
This text appears to describe the layers and components of some sort of adhesive product, possibly a medical patch or bandage. The layers include a backing layer, an adhesive film layer, a separating layer, and a drug/polymer adhesive matrix layer. Additionally, there is a peel-off release liner.*
Figure 2 (Buprenorphine 03)
This is a graph depicting the concentration (pg/mL) of buprenorphine in patients using a transdermal system over a period of 25 days. The data is divided into three groups, with each group wearing the system for seven days before removal. The graph shows the concentration decreasing gradually over time.*
Figure 3 (Buprenorphine 04)
Figure 4 (Buprenorphine 05)
This document appears to be a table or chart displaying the percentage of patients who have experienced pain improvement using two types of buprenorphine patches: Transdermal Systam 5 and Transdermal System 20. The chart also shows the percentage of reduction or improvement in pain for each patch type.*
Figure A (Buprenorphine 06)
Figure B (Buprenorphine 07)
Figure C (Buprenorphine 08)
Figure D (Buprenorphine 09)
Figure E (Buprenorphine 10)
Figure F (Buprenorphine 11)
Figure G (Buprenorphine 12)
Figure H (Buprenorphine 13)
Figure I (Buprenorphine 14)
Figure J (Buprenorphine 15)
Figure K (Buprenorphine 16)
Figure L (Buprenorphine 17)
Figure M (Buprenorphine 18)
Figure N (Buprenorphine 19)
Figure O (Buprenorphine 20)
Principal Display Panel (5 mcg/hour Patch Pouch Carton)
This is a product description for the Buprenorphine Transdermal System. The package contains four disposable units with each unit capable of delivering 5 mog per hour of buprenorphine. This transdermal system provides systemic delivery of buprenorphine for seven days. It is meant to be used for chronic pain that cannot be treated with immediate-release opioids or non-opioid analgesics and not for intermittent (on an as-needed basis) pain relief. The package should not be used for life-threatening breathing problems. The product has an NDC code of 42858-750-40.*
Principal Display Panel (7.5 mcg/hour Patch Pouch Carton)
This is the package insert for Buprenorphine Transdermal System containing four transdermal systems with a systemic delivery of 7.5 mg per hour of buprenorphine for seven days, intended for use in pain management. This system is not recommended for pain that can be treated with immediate-release opioids or non-opioid analgesics, or for intermittent pain. This insert includes the NDC code, a warning about the serious or life-threatening breathing problems that can occur with use, and instructions for disposal. There are also other characters that are not recognized.*
Principal Display Panel (10 mcg/hour Patch Pouch Carton)
Buprenorphine Transdermal System is a medication designed for systemic delivery of 10 mg per hour of buprenorphine for seven days. Each package of the medication contains 4 transdermal systems and is intended for one-time use only. It should not be used for treating pain that can be treated with immediate-release opioids or non-opioid analgesics. The medication is also not intended to be used for intermittent (on an as-needed basis) pain relief. The package includes disposal units for safe disposal. For further information, see the pharmacy label.*
Principal Display Panel (15 mcg/hour Patch Pouch Carton)
The text is a product label for Buprenorphine Transdermal System, a system that delivers 15 mcg per hour of Buprenorphine for seven days and provides systemic analgesia. It warns against using the system for treating pain that can be treated with other medications and for patients who have serious or life-threatening breathing problems. It also provides product information, such as the NDC code and instructions on how to use and dispose of the product.*
Principal Display Panel (20 mcg/hour Patch Pouch Carton)
This text appears to be a combination of various information. It includes a medication name, Buprenorphine Transdermal System, which is used to deliver buprenorphine through the skin continuously for seven days to treat pain. The dosage mentions a systemic delivery of 20 mcg per hour of the medication, and there is a warning that it should not be used for certain types of pain. The text also confirms that the package contains four transdermal systems and a disposal unit. There are several other lines containing random characters, numbers, and symbols that do not provide any relevant information. Overall, the text appears to be a mix of useful information and irrelevant characters that require further analysis to provide a meaningful description.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
